HPGC(SH:600664)2025-04-25 13:33Financial Performance - The company's operating revenue for Q1 2025 was CNY 4,174,424,028.39, representing a 0.78% increase compared to CNY 4,142,160,958.07 in the same period last year[5]. - Net profit attributable to shareholders increased by 20.48% to CNY 212,929,359.73 from CNY 176,741,385.26 year-on-year[5]. - The net profit after deducting non-recurring gains and losses rose by 28.06% to CNY 203,986,037.99 compared to CNY 159,290,806.61 in the previous year[5]. - The company's net profit for Q1 2025 was CNY 218.73 million, an increase of 14.9% compared to CNY 190.31 million in Q1 2024[24]. - The total comprehensive income for Q1 2025 was CNY 218.74 million, compared to CNY 190.31 million in Q1 2024, reflecting a growth of 14.9%[24]. Cash Flow and Financial Position - The net cash flow from operating activities was negative at CNY -464,573,942.93, a decline of 71.56% from CNY -270,799,005.53 in the same period last year[5]. - The company's cash flow from financing activities was negative CNY 271.12 million in Q1 2025, a decline from positive CNY 126.27 million in Q1 2024[28]. - The company's cash and cash equivalents decreased to RMB 2,802,289,671.46 from RMB 3,634,381,413.10, representing a decline of approximately 22.9%[17]. - The cash and cash equivalents at the end of Q1 2025 were CNY 2.77 billion, a slight decrease from CNY 2.80 billion at the end of Q1 2024[28]. Assets and Liabilities - Total assets decreased by 3.57% to CNY 14,093,731,165.68 from CNY 14,615,758,011.08 at the end of the previous year[5]. - Current assets as of March 31, 2025, totaled RMB 10,498,968,223.29, down from RMB 10,978,679,688.33 as of December 31, 2024, indicating a decrease of about 4.4%[17]. - Total liabilities decreased to RMB 7,785,724,064.16 as of March 31, 2025, from RMB 8,526,490,627.20 at the end of 2024, a reduction of approximately 8.7%[19]. - The total assets of the company were RMB 14,093,731,165.68 as of March 31, 2025, down from RMB 14,615,758,011.08 at the end of 2024, indicating a decrease of about 3.6%[19]. - The company reported a decrease in inventory to RMB 1,825,189,539.55 from RMB 1,891,061,725.71, reflecting a decline of approximately 3.5%[17]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 104,431[12]. - The largest shareholder, Harbin Pharmaceutical Group Co., Ltd., holds 46.58% of the shares, with 926,857,248 shares pledged[13]. - Shareholders' equity attributable to the parent company increased by 3.98% to CNY 5,562,723,133.49 from CNY 5,349,779,547.13 at the end of the previous year[5]. - The total equity attributable to shareholders increased to RMB 5,562,723,133.49 from RMB 5,349,779,547.13, marking an increase of about 4.0%[19]. Operating Costs and Expenses - The company reported a total operating cost of CNY 3.91 billion in Q1 2025, compared to CNY 3.91 billion in Q1 2024, indicating a stable cost structure[23]. - Research and development expenses increased to CNY 31.12 million in Q1 2025, up from CNY 25.27 million in Q1 2024, representing a growth of 23.3%[23]. - The company incurred a financial expense of CNY 7.41 million in Q1 2025, compared to CNY 3.23 million in Q1 2024, indicating an increase of 129.5%[23]. - The company reported a significant increase in financial expenses by 129.62%, amounting to an increase of CNY 418 million, primarily due to a decrease in deposit interest rates[9]. Market Activity - The company has not indicated any significant new product launches or market expansions during this reporting period[15].